AXSANA – AXillary Surgery After NeoAdjuvant Treatment (EUBREAST-3): current status of the international prospective multicenter cohort study evaluating different surgical methods of axillary staging in clinically node-positive breast cancer patients treated with neoadjuvant chemotherapy (NCT04373655)

S. Fröhlich,S. Hartmann,M. Banys-Paluchowski,E. Stickeler,J. de Boniface,O. Gentilini,F. Ruf,M. Thill,M. Hauptmann,A. Rief, T. Berger, K. Wihlfahrt,G. Karadeniz Cakmak,I. Rubio, M.L. Gaspari,M. Kontos,E.-A. Bonci,L. Niinikoski,D. Murawa,D. Pinto,F. Peintinger, E. Schlichting, P. Krivorotko, L.Rebaza Vasquez, H. Valiyeva, N. Helidon,M. Appelgren,M. Hahn, E. Thiemann, G. Kaltenecker,T. Kühn

Senologie - Zeitschrift für Mammadiagnostik und -therapie 41. Jahrestagung der Deutschen Gesellschaft für Senologie e.V. – Gemeinsam gegen Brustkrebs: optimale Behandlung für jede Patientin（2022）

Cited 0|Views11

No score

Abstract

Background The optimal surgical axillary staging for breast cancer patients converting from cN+ to ycN0 after neoadjuvant chemotherapy (NACT) is controversial. The ongoing AXSANA study aims to assess whether de-escalation of axillary surgery is possible in these patients without a loss of oncologic safety and whether it can improve quality of life. The current status of recruitment and axillary management of the patients included so far are presented.

Translated text

Key words

axillary surgery,neoadjuvant chemotherapy,axillary staging,neoadjuvant treatment,node-positive

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined